Parkinson's drug side effect trial halted early
NCT ID NCT03146130
First seen Jun 14, 2026 · Last updated Jun 23, 2026 · Updated 1 time
Summary
This study tested whether N-acetylcysteine (NAC), a common supplement, could help with impulse control disorders caused by Parkinson's medications. The trial planned to include 14 people with mild-to-moderate symptoms, but it was terminated early. Because it stopped before completion, we cannot draw reliable conclusions about NAC's effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMPULSE CONTROL DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU Amiens Picardie
Amiens, Picardie, 80054, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
N-acetylcysteine (NAC)
What this could lead to
If it worked, NAC could offer a way to reduce impulse control problems in people with Parkinson's without changing their main medications.
What could go wrong
The trial was terminated early and only enrolled 14 people, so results are very limited. It is unclear if NAC is effective or safe for this use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.